Acadian Asset Management LLC Buys 2,663,270 Shares of GSK PLC Sponsored ADR $GSK

Acadian Asset Management LLC boosted its stake in shares of GSK PLC Sponsored ADR (NYSE:GSK) by 201.9% in the first quarter, Holdings Channel reports. The institutional investor owned 3,982,324 shares of the pharmaceutical company’s stock after purchasing an additional 2,663,270 shares during the period. Acadian Asset Management LLC’s holdings in GSK were worth $154,244,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in GSK. HHM Wealth Advisors LLC increased its position in GSK by 222.2% during the 1st quarter. HHM Wealth Advisors LLC now owns 667 shares of the pharmaceutical company’s stock valued at $26,000 after buying an additional 460 shares in the last quarter. Costello Asset Management INC bought a new position in GSK in the 1st quarter valued at approximately $31,000. Richardson Financial Services Inc. lifted its position in GSK by 127.9% in the 1st quarter. Richardson Financial Services Inc. now owns 841 shares of the pharmaceutical company’s stock valued at $33,000 after acquiring an additional 472 shares in the last quarter. Olde Wealth Management LLC bought a new position in GSK in the 1st quarter valued at approximately $36,000. Finally, Cary Street Partners Investment Advisory LLC lifted its position in GSK by 525.9% in the 1st quarter. Cary Street Partners Investment Advisory LLC now owns 1,014 shares of the pharmaceutical company’s stock valued at $39,000 after acquiring an additional 852 shares in the last quarter. Institutional investors own 15.74% of the company’s stock.

GSK Stock Down 0.8%

GSK opened at $40.47 on Wednesday. The company has a current ratio of 0.87, a quick ratio of 0.57 and a debt-to-equity ratio of 1.07. GSK PLC Sponsored ADR has a 1-year low of $31.72 and a 1-year high of $44.03. The company has a market capitalization of $82.43 billion, a PE ratio of 18.75, a PEG ratio of 2.00 and a beta of 0.53. The firm’s 50 day simple moving average is $38.59 and its two-hundred day simple moving average is $38.40.

GSK (NYSE:GSK) last released its quarterly earnings results on Wednesday, July 30th. The pharmaceutical company reported $1.23 earnings per share for the quarter, topping the consensus estimate of $1.12 by $0.11. GSK had a net margin of 10.81% and a return on equity of 49.22%. The business had revenue of $10.64 billion for the quarter, compared to the consensus estimate of $7.92 billion. During the same period last year, the firm earned $0.43 earnings per share. The company’s quarterly revenue was up 1.3% on a year-over-year basis. GSK has set its FY 2025 guidance at 4.590-4.590 EPS. As a group, equities analysts forecast that GSK PLC Sponsored ADR will post 4.14 EPS for the current year.

GSK Cuts Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, October 9th. Shareholders of record on Friday, August 15th will be given a $0.4206 dividend. The ex-dividend date is Friday, August 15th. This represents a $1.68 annualized dividend and a yield of 4.2%. GSK’s dividend payout ratio (DPR) is presently 77.78%.

Analyst Ratings Changes

Several equities analysts recently issued reports on the company. Wall Street Zen raised GSK from a “buy” rating to a “strong-buy” rating in a research report on Friday, September 5th. Berenberg Bank reiterated a “hold” rating on shares of GSK in a research note on Tuesday, June 3rd. Six equities research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, GSK presently has a consensus rating of “Reduce” and a consensus price target of $37.38.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.